<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="216163">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00271180</url>
  </required_header>
  <id_info>
    <org_study_id>602</org_study_id>
    <nct_id>NCT00271180</nct_id>
  </id_info>
  <brief_title>Product Performance Report: Evaluate Long-term Reliability &amp; Performance of Medtronic Marketed Cardiac Therapy Products</brief_title>
  <acronym>PPR</acronym>
  <official_title>Medtronic CRDM Product Performance Report</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medtronic Cardiac Rhythm and Heart Failure</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medtronic Cardiac Rhythm and Heart Failure</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main purpose of the Product Performance Report (formerly referred to as System Longevity
      Study) is to evaluate long-term performance of Medtronic market-released cardiac rhythm
      products by analyzing product survival probabilities.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      All Medtronic market-released leads and all market-released IPG, ICD and CRT devices are
      eligible to be included in this study.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>January 1983</start_date>
  <completion_date type="Anticipated">December 2024</completion_date>
  <primary_completion_date type="Anticipated">December 2024</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Lead related complications for each lead model.</measure>
    <time_frame>Ongoing: Implant to the cardiac lead is terminated from the study if the patient exit, patient death, or out-of-service (e.g. deactivated/inactive).</time_frame>
    <description>All follow-up visits will be utilized in the analyses. This is an observational study that does not have a statistically powered primary hypothesis. Therefore, a specific study sample size is not applicable.</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">15000</enrollment>
  <condition>Arrhythmia</condition>
  <condition>Bradycardia</condition>
  <condition>Heart Failure</condition>
  <condition>Sinus Tachycardia</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Subjects implanted with Medtronic qualifying cardiac rhythm product.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Subjects who meet the following inclusion criteria and do not meet any of the following
        exclusion criteria are eligible for enrollment.

        Inclusion Criteria:

        â€¢ Subject or appropriate legal guardians provide written informed consent and/or
        authorization for access to and use of health information as required by an institution's
        IRB/MEC/REB

        AND one of the following must also apply:

          -  Subject is indicated for implant or within 30 days post-implant of at least one
             Medtronic market-released product used for a pacing, sensing or defibrillation
             application

          -  Subjects who participated in a qualifying study (IDE) of a Medtronic market-released
             product with complete implant and follow-up data and subject or appropriate legal
             guardian authorizes release of subject study data

        Exclusion Criteria:

          -  Subjects who are, or will be inaccessible for follow-up

          -  Subjects with exclusion criteria required by local law (EMEA only)

          -  Subjects receiving an implant of a Medtronic device at a non-participating center and
             the implant data and current status cannot be confirmed within 30 days after implant

          -  Subjects implanted with a Medtronic device whose predetermined enrollment limit for
             that specific product has been exceeded
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Product Performance Report Study Leader</last_name>
    <role>Study Chair</role>
    <affiliation>Medtronic</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Medtronic CRM Clinical Trials</last_name>
    <email>medtroniccrmtrials@medtronic.com</email>
  </overall_contact>
  <location>
    <facility>
      <address>
        <city>Lebanon</city>
        <state>New Hampshire</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Linz</city>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Hasselt</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Copenhagen</city>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Kobenhavn</city>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Marseille</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Nantes</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Homburg/Saar</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Reggio Emilia</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Udine</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Eindhoven</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Rotterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Beograd</city>
        <country>Serbia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Skovde</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Zurich</city>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Belgium</country>
    <country>Denmark</country>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>Serbia</country>
    <country>Sweden</country>
    <country>Switzerland</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Australia</country>
    <country>Canada</country>
    <country>Finland</country>
    <country>Former Serbia and Montenegro</country>
    <country>Greece</country>
    <country>Spain</country>
  </removed_countries>
  <verification_date>September 2014</verification_date>
  <lastchanged_date>September 12, 2014</lastchanged_date>
  <firstreceived_date>December 28, 2005</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cardiac Pacing</keyword>
  <keyword>Implantable Cardioverter Defibrillator</keyword>
  <keyword>pacemaker</keyword>
  <keyword>Sinus Bradycardia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Heart Failure</mesh_term>
    <mesh_term>Tachycardia</mesh_term>
    <mesh_term>Bradycardia</mesh_term>
    <mesh_term>Tachycardia, Sinus</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
